Related references
Note: Only part of the references are listed.Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee
Asher Kornbluth et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Importance of Mucosal Healing in Ulcerative Colitis
Gary R. Lichtenstein et al.
INFLAMMATORY BOWEL DISEASES (2010)
World Gastroenterology Organization Practice Guidelines for the Diagnosis and Management of IBD in 2010
Charles N. Bernstein et al.
INFLAMMATORY BOWEL DISEASES (2010)
Treatment of ulcerative colitis from the patient's perspective: a survey of preferences and satisfaction with therapy
J. R. Gray et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares
P. D. R. Higgins et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Mesalamine Once Daily Is More Effective Than Twice Daily in Patients With Quiescent Ulcerative Colitis
Axel U. Dignass et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2009)
Home Telemanagement for Patients with Ulcerative Colitis (UC HAT)
Raymond K. Cross et al.
DIGESTIVE DISEASES AND SCIENCES (2009)
Patient reported symptoms during an ulcerative colitis flare: A Qualitative Focus Group Study
Akbar K. Waljee et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2009)
Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial
W. Kruis et al.
GUT (2009)
Effect of Extended MMX Mesalamine Therapy for Acute, Mild-to-Moderate Ulcerative Colitis
Michael A. Kamm et al.
INFLAMMATORY BOWEL DISEASES (2009)
Impact of Ulcerative Colitis from Patients' and Physicians' Perspectives: Results from the UC: NORMAL Survey
David T. Rubin et al.
INFLAMMATORY BOWEL DISEASES (2009)
Fecal Calprotectin and Lactoferrin for the Prediction of Inflammatory Bowel Disease Relapse
Javier P. Gisbert et al.
INFLAMMATORY BOWEL DISEASES (2009)
5-ASA in ulcerative colitis: Improving treatment compliance
Cosimo Prantera et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2009)
Review article: medication non-adherence in ulcerative colitis - strategies to improve adherence with mesalazine and other maintenance therapies
A. B. Hawthorne et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2008)
Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: Performance of fecal lactoferrin, calprotectin, and PMN-Elastase, CRP, and clinical indices
Jost Langhorst et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2008)
Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis
M. A. Kamm et al.
GUT (2008)
Identification of symptom domains in ulcerative colitis that occur frequently during flares and are responsive to changes in disease activity
Joel C. Joyce et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2008)
Endoscopic healing should be a goal for everyone with ulcerative colitis
Sunanda Kane
INFLAMMATORY BOWEL DISEASES (2008)
European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis
E. F. Stange et al.
JOURNAL OF CROHNS & COLITIS (2008)
Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared with 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial
Stephen B. Hanauer et al.
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2007)
Mind the gap : An unmet need for new therapy in IBD
Seymour Katz
JOURNAL OF CLINICAL GASTROENTEROLOGY (2007)
Mucosal healing in inflammatory bowel disease: Results from a Norwegian population-based cohort
Kathrine Frey Froslie et al.
GASTROENTEROLOGY (2007)
Outcome measurement in clinical trials for Ulcerative Colitis: towards standardisation
Rachel M. Cooney et al.
TRIALS (2007)
Trends in hospitalization rates for inflammatory bowel disease in the United States
Meenakshi Bewtra et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2007)
The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients
Brian G. Feagan et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2007)
Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?
Paul Rutgeerts et al.
GUT (2007)
Interventions to enhance medication adherence in chronic medical conditions - A systematic review
Sunil Kripalani et al.
ARCHIVES OF INTERNAL MEDICINE (2007)
A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis
Chinyu Su et al.
GASTROENTEROLOGY (2007)
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis
Geert D'Haens et al.
GASTROENTEROLOGY (2007)
Once-daily, high-concentration MMX mesalamine in active ulcerative colitis
Michael A. Kamm et al.
GASTROENTEROLOGY (2007)
Management of inflammatory bowel diseases in Eastern Europe
L Lakatos et al.
POSTGRADUATE MEDICAL JOURNAL (2006)
Systematic review: adherence issues in the treatment of ulcerative colitis
SV Kane
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: The ASCEND II trial
SB Hanauer et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2005)
Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study
P Marteau et al.
GUT (2005)
Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis
PDR Higgins et al.
GUT (2005)
Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study
OA Paoluzi et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2005)
Is endoscopy necessary for the measurement of disease activity in ulcerative colitis?
PDR Higgins et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2005)
Guidelines for the management of inflammatory bowel disease in adults
MJ Carter et al.
GUT (2004)
Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis
A Sinha et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Medication Nonadherence and the outcomes of patients with quiescent ulcerative colitis
S Kane et al.
AMERICAN JOURNAL OF MEDICINE (2003)
Evaluation of the clinical course of acute attacks in patients with ulcerative colitis through the use of an activity index
M Seo et al.
JOURNAL OF GASTROENTEROLOGY (2002)
Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis
A Bitton et al.
GASTROENTEROLOGY (2001)
Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease
JA Tibble et al.
GASTROENTEROLOGY (2000)
Share Paper
